跳至主要内容
临床试验/JPRN-UMIN000021928
JPRN-UMIN000021928已完成未知

The efficacy of third or fourth line H. pylori eradication therapy with refabutin-amoxicillin-vonaprazan 7day regimen - The efficacy of third or fourth line H. pylori eradication therapy with refabutin-amoxicillin-vonaprazan 7day regimen

Keio University School of Medicine0 个研究点目标入组 66 人开始时间: 2016年4月15日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
66

研究概览

简要总结

Intention-to-treat and per-protocol analyses showed that our regimen resulted in a high eradication rate (91.2%, 95% CI: 84%-99% and 92.7%, 95% CI: 86%-100%, respectively). Adverse events occurred in 31.6% of the patients, and two patients discontinued the therapy.

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1. Patients with allergy for rifamycins 2. Patients with past histry of tuberculosis or nontuberculous mycobacterial infection 3. Patients with allergy for PPIs 4. Patients with allergy for penicillin 5. Patients with severe liver injury and/or severe renal damage 6. Pregnancy or possible pregnancy 7. Patients who are taking voriconazole 8. Patients with uveitis 9. Patients who were recognized as inappropriate for entry

研究者

相似试验